Who is sponsoring NCT06838832?

NCT06838832 is sponsored by Chinese PLA General Hospital.

What drugs are being tested in NCT06838832?

Interventions in NCT06838832: Allogenic CD19-CAR-γδT cell, Fludarabine, Cyclophosphamide.

What condition does NCT06838832 study?

NCT06838832 studies Non-hodgkin Lymphoma,B Cell.

Is NCT06838832 still recruiting?

NCT06838832 is currently recruiting now. Last updated 30 July 2025.

Last reviewed 2025-07-30 · How we verify

NCT06838832

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL

Recruiting now Phase 1, PHASE2 Last updated 30 July 2025

What this trial tests

Phase 1, PHASE2 trial testing Allogenic CD19-CAR-γδT cell in Non-hodgkin Lymphoma,B Cell in 30 participants. Currently enrolling.

Timeline

27 July 2025

Primary endpoint
1 March 2027

1 March 2028

Quick facts

Lead sponsor	Chinese PLA General Hospital
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	27 July 2025
Primary completion	1 March 2027
Estimated completion	1 March 2028
Sites	1 location across China

Drugs / interventions tested

Allogenic CD19-CAR-γδT cell
Fludarabine (FLUDARABINE) — full drug profile →
Cyclophosphamide (cyclophosphamide) — full drug profile →

Conditions studied

Non-hodgkin Lymphoma,B Cell — all drugs for Non-hodgkin Lymphoma,B Cell →

Sponsor

Chinese PLA General Hospital

Who can join

Adults 18 to 75, any sex, with Non-hodgkin Lymphoma,B Cell. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

CD19-CAR-γδT cell therapy is a cellular immunotherapy targeting CD19 to perform CAR modification on allogeneic γδT cells. A novel version of the CAR-γδT product by gene editing (QH103E) that has been validated for resistance to alloreactive T cell killing and enhancement of memory efficacy will be used in this study. This is a single center, prospective, open-label, single-arm, phase 1/2 study. A total of around 30 patients with relapsed or refractory (r/r) B-cell non-Hodgkin's lymphoma (NHL) will be enrolled in the study and receive QH103E product infusion. Phase 1 (n=9 to 12) is dose escalation part, and phase 2 (n=15 to 20) is expansion cohort part. The primary objective of this study was to evaluate the safety and efficacy of QH103E in patients with r/r B-cell NHL.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Diverse Subsets of γδT Cells and Their Specific Functions Across Liver Diseases.
Zhan C, Peng C, Wei H, Wei K, et al · · 2025 · cited 4× · PMID 40141420 · DOI 10.3390/ijms26062778
Mechanisms of Resistance to CAR T-Cells and How to Overcome Them.
Legato L, Bisio M, Fasano F, Benevolo Savelli C, et al · · 2025 · cited 3× · PMID 40981226 · DOI 10.3390/mps8050108
Re-Tooling of γδ T Cells for Cancer Immunotherapy Using Advanced Manufacturing and Genetic Engineering.
Lim BJL, Maher J. · · 2026 · PMID 41892285 · DOI 10.3390/cells15060494
Immune Exhaustion in Chronic Infection and Cancer: Signaling Pathways and Therapeutic Interventions.
Song Y, Mo Y, Chen S, Chen Y, et al · · 2026 · PMID 41768369 · DOI 10.1002/mco2.70635

Verify or expand the search:

Other recruiting trials for Non-hodgkin Lymphoma,B Cell

Currently open trials in the same condition.

NCT07248163 — Universal CAR-T Cell Therapy for NHL · NA · recruiting
NCT06716164 — Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research · EARLY_PHASE1 · recruiting
NCT05909059 — CAR T-cell Therapy in Patients With Renal Dysfunction · Phase 2 · recruiting
NCT06346912 — CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL · EARLY_PHASE1 · recruiting
NCT06321289 — Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL · Phase 1, PHASE2 · recruiting

Other Chinese PLA General Hospital trials

Trials by the same sponsor.

NCT07294755 — The Impact of Intrapleural Block on Postoperative Pain Caused by Drainage Tubes After Thoracoscopic Surgery · NA · not yet recruiting
NCT07536607 — Predictive Role of Photon Counting Computed Tomography in Acute Coronary Syndrom Patients · not yet recruiting
NCT07489157 — Real-Time End-Tidal Carbon Dioxide Monitoring for Early Warning of Hypoxemia in Painless Gastrointestinal Endoscopy · NA · not yet recruiting
NCT07494981 — Individualized Precision Therapy With Ceftazidime and Avibactam Guided by PK/PD in Geriatric Populations · not yet recruiting
NCT07496008 — Individualized Precision Isavuconazole Therapy Guided by PK/PD Principles for the Geriatric Population · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06838832 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese PLA General Hospital
Last refreshed: 30 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06838832.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing